Becton Dickinson (BDX) has been making strides in both
business growth and
innovation. Its
financial management in terms of debt has been commended, while its position in the portfolios of investors and institutions has been consistently bullish.
BD announced a single-cell research automation solution, giving a nudge towards a
fresh innovative approach in research. It also completed the acquisition of Edwards Lifesciences'
Critical Care Product Group for $4.2 billion to enhance the scope of its smart connected care solutions.
Boston Trust Walden Corp and
Beese Fulmer Investment Management Inc reduced their stakes in BDX. While
Eastern Bank and
Vest Financial LLC increased theirs. BD's Short Interest fell 9.2% in September, suggesting higher market expectations.
BD is facing lawsuits regarding hernia litigation with settlements expected over $1 billion. The company is rated as a good long-term value, growth, and momentum stock by numerous stock market experts. Also, BD's Q3 earnings topped estimates, with margins expanding.
BD has announced key leadership changes with Patrick Jeukenne named as president of BD Pharmaceutical Systems, Michael Feld as President of Life Sciences Segment, and Rian Seger as President of BD Surgery.
The company is also in collaboration with Quest Diagnostics for development of Companion Diagnostics for diseases.
Becton Dickinson and BDX News Analytics from Thu, 01 Feb 2024 08:00:00 GMT to Sat, 26 Oct 2024 16:35:52 GMT -
